AAPL345.36-1.74 (-0.50%) ▼|ABBV287.64+1.25 (+0.44%) ▲|ABT103.21+0.11 (+0.11%) ▲|ACN245.06+9.90 (+4.21%) ▲|ADBE247.73-0.64 (-0.26%) ▼|AMAT413.18+17.25 (+4.36%) ▲|AMD566.94+6.68 (+1.19%) ▲|AMGN449.95+2.00 (+0.45%) ▲|AMT177.77-6.07 (-3.30%) ▼|AMZN252.54-0.56 (-0.22%) ▼|AVGO347.23+4.90 (+1.43%) ▲|AXP316.12+3.21 (+1.02%) ▲|BA166.71-1.47 (-0.87%) ▼|BAC51.08+0.40 (+0.79%) ▲|BKNG148.00-2.15 (-1.43%) ▼|BLK1,150.65+14.60 (+1.29%) ▲|BMY60.42-1.13 (-1.84%) ▼|BNY148.96+1.38 (+0.94%) ▲|BRK-B544.11+1.12 (+0.21%) ▲|C124.09+1.40 (+1.14%) ▲|CAT715.96+2.65 (+0.37%) ▲|CL91.91-0.26 (-0.28%) ▼|CMCSA21.68-0.17 (-0.76%) ▼|COF204.41+0.97 (+0.47%) ▲|COP150.26+2.30 (+1.55%) ▲|COST983.47-8.67 (-0.87%) ▼|CRM240.71-0.18 (-0.07%) ▼|CSCO109.93-1.45 (-1.30%) ▼|CVS90.66-0.47 (-0.52%) ▼|CVX231.27+3.04 (+1.33%) ▲|DE640.21+0.63 (+0.10%) ▲|DHR234.37+2.37 (+1.02%) ▲|DIS109.14-1.09 (-0.99%) ▼|DUK124.73-0.07 (-0.06%) ▼|EMR167.49+1.22 (+0.73%) ▲|FDX301.65-5.45 (-1.77%) ▼|GD354.34-0.55 (-0.16%) ▼|GE303.32+5.66 (+1.90%) ▲|GEV890.28-4.80 (-0.54%) ▼|GILD159.23+0.15 (+0.09%) ▲|GM81.11+0.57 (+0.71%) ▲|GOOG320.44+3.61 (+1.14%) ▲|GOOGL323.80+3.22 (+1.00%) ▲|GS923.33+11.56 (+1.27%) ▲|HD318.52+0.02 (+0.01%) ▲|HON219.28+0.47 (+0.21%) ▲|IBM251.45+1.20 (+0.48%) ▲|INTC93.80+0.06 (+0.06%) ▲|INTU330.13+1.68 (+0.51%) ▲|ISRG447.28+1.40 (+0.31%) ▲|JNJ270.25+1.52 (+0.57%) ▲|JPM339.65+3.86 (+1.15%) ▲|KO91.83+0.65 (+0.71%) ▲|LIN508.40-0.25 (-0.05%) ▼|LLY1,286.30+4.39 (+0.34%) ▲|LMT629.32+6.33 (+1.02%) ▲|LOW198.75+0.57 (+0.29%) ▲|LRCX254.12+13.27 (+5.51%) ▲|MA613.49+3.64 (+0.60%) ▲|MCD251.60+2.13 (+0.85%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.87+0.92 (+0.98%) ▲|META613.34-6.85 (-1.10%) ▼|MMM172.23+0.65 (+0.38%) ▲|MO73.48-0.01 (-0.01%) ▼|MRK140.34-1.49 (-1.05%) ▼|MS189.48+2.57 (+1.38%) ▲|MSFT528.46-2.88 (-0.54%) ▼|MU972.96+44.20 (+4.76%) ▲|NEE81.95-0.47 (-0.57%) ▼|NFLX61.76-0.76 (-1.22%) ▼|NKE37.26-0.30 (-0.80%) ▼|NOW150.63-4.15 (-2.68%) ▼|NVDA217.08-0.87 (-0.40%) ▼|ORCL130.98+0.45 (+0.34%) ▲|PEP132.30-1.20 (-0.90%) ▼|PFE29.38-0.43 (-1.43%) ▼|PG159.22-0.01 (-0.01%) ▼|PLTR194.37-4.36 (-2.19%) ▼|PM202.89+0.27 (+0.13%) ▲|QCOM181.52-2.66 (-1.44%) ▼|RTX197.12+2.52 (+1.30%) ▲|SBUX104.33+1.29 (+1.25%) ▲|SCHW88.86-0.44 (-0.49%) ▼|SO92.58-0.07 (-0.08%) ▼|SPG212.19-0.10 (-0.04%) ▼|T21.04+0.10 (+0.45%) ▲|TMO700.50+7.48 (+1.08%) ▲|TMUS146.74-0.09 (-0.06%) ▼|TSLA401.00-6.46 (-1.59%) ▼|TXN305.50-3.41 (-1.10%) ▼|UBER65.57-0.21 (-0.32%) ▼|UNH412.43+2.04 (+0.50%) ▲|UNP301.70+1.82 (+0.61%) ▲|UPS104.89-1.20 (-1.13%) ▼|USB59.65-0.10 (-0.16%) ▼|V401.72-0.15 (-0.04%) ▼|VZ43.76-0.18 (-0.40%) ▼|WFC84.38+1.72 (+2.07%) ▲|WMT118.74-0.58 (-0.49%) ▼|XOM183.42+3.51 (+1.95%) ▲|AAPL345.36-1.74 (-0.50%) ▼|ABBV287.64+1.25 (+0.44%) ▲|ABT103.21+0.11 (+0.11%) ▲|ACN245.06+9.90 (+4.21%) ▲|ADBE247.73-0.64 (-0.26%) ▼|AMAT413.18+17.25 (+4.36%) ▲|AMD566.94+6.68 (+1.19%) ▲|AMGN449.95+2.00 (+0.45%) ▲|AMT177.77-6.07 (-3.30%) ▼|AMZN252.54-0.56 (-0.22%) ▼|AVGO347.23+4.90 (+1.43%) ▲|AXP316.12+3.21 (+1.02%) ▲|BA166.71-1.47 (-0.87%) ▼|BAC51.08+0.40 (+0.79%) ▲|BKNG148.00-2.15 (-1.43%) ▼|BLK1,150.65+14.60 (+1.29%) ▲|BMY60.42-1.13 (-1.84%) ▼|BNY148.96+1.38 (+0.94%) ▲|BRK-B544.11+1.12 (+0.21%) ▲|C124.09+1.40 (+1.14%) ▲|CAT715.96+2.65 (+0.37%) ▲|CL91.91-0.26 (-0.28%) ▼|CMCSA21.68-0.17 (-0.76%) ▼|COF204.41+0.97 (+0.47%) ▲|COP150.26+2.30 (+1.55%) ▲|COST983.47-8.67 (-0.87%) ▼|CRM240.71-0.18 (-0.07%) ▼|CSCO109.93-1.45 (-1.30%) ▼|CVS90.66-0.47 (-0.52%) ▼|CVX231.27+3.04 (+1.33%) ▲|DE640.21+0.63 (+0.10%) ▲|DHR234.37+2.37 (+1.02%) ▲|DIS109.14-1.09 (-0.99%) ▼|DUK124.73-0.07 (-0.06%) ▼|EMR167.49+1.22 (+0.73%) ▲|FDX301.65-5.45 (-1.77%) ▼|GD354.34-0.55 (-0.16%) ▼|GE303.32+5.66 (+1.90%) ▲|GEV890.28-4.80 (-0.54%) ▼|GILD159.23+0.15 (+0.09%) ▲|GM81.11+0.57 (+0.71%) ▲|GOOG320.44+3.61 (+1.14%) ▲|GOOGL323.80+3.22 (+1.00%) ▲|GS923.33+11.56 (+1.27%) ▲|HD318.52+0.02 (+0.01%) ▲|HON219.28+0.47 (+0.21%) ▲|IBM251.45+1.20 (+0.48%) ▲|INTC93.80+0.06 (+0.06%) ▲|INTU330.13+1.68 (+0.51%) ▲|ISRG447.28+1.40 (+0.31%) ▲|JNJ270.25+1.52 (+0.57%) ▲|JPM339.65+3.86 (+1.15%) ▲|KO91.83+0.65 (+0.71%) ▲|LIN508.40-0.25 (-0.05%) ▼|LLY1,286.30+4.39 (+0.34%) ▲|LMT629.32+6.33 (+1.02%) ▲|LOW198.75+0.57 (+0.29%) ▲|LRCX254.12+13.27 (+5.51%) ▲|MA613.49+3.64 (+0.60%) ▲|MCD251.60+2.13 (+0.85%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.87+0.92 (+0.98%) ▲|META613.34-6.85 (-1.10%) ▼|MMM172.23+0.65 (+0.38%) ▲|MO73.48-0.01 (-0.01%) ▼|MRK140.34-1.49 (-1.05%) ▼|MS189.48+2.57 (+1.38%) ▲|MSFT528.46-2.88 (-0.54%) ▼|MU972.96+44.20 (+4.76%) ▲|NEE81.95-0.47 (-0.57%) ▼|NFLX61.76-0.76 (-1.22%) ▼|NKE37.26-0.30 (-0.80%) ▼|NOW150.63-4.15 (-2.68%) ▼|NVDA217.08-0.87 (-0.40%) ▼|ORCL130.98+0.45 (+0.34%) ▲|PEP132.30-1.20 (-0.90%) ▼|PFE29.38-0.43 (-1.43%) ▼|PG159.22-0.01 (-0.01%) ▼|PLTR194.37-4.36 (-2.19%) ▼|PM202.89+0.27 (+0.13%) ▲|QCOM181.52-2.66 (-1.44%) ▼|RTX197.12+2.52 (+1.30%) ▲|SBUX104.33+1.29 (+1.25%) ▲|SCHW88.86-0.44 (-0.49%) ▼|SO92.58-0.07 (-0.08%) ▼|SPG212.19-0.10 (-0.04%) ▼|T21.04+0.10 (+0.45%) ▲|TMO700.50+7.48 (+1.08%) ▲|TMUS146.74-0.09 (-0.06%) ▼|TSLA401.00-6.46 (-1.59%) ▼|TXN305.50-3.41 (-1.10%) ▼|UBER65.57-0.21 (-0.32%) ▼|UNH412.43+2.04 (+0.50%) ▲|UNP301.70+1.82 (+0.61%) ▲|UPS104.89-1.20 (-1.13%) ▼|USB59.65-0.10 (-0.16%) ▼|V401.72-0.15 (-0.04%) ▼|VZ43.76-0.18 (-0.40%) ▼|WFC84.38+1.72 (+2.07%) ▲|WMT118.74-0.58 (-0.49%) ▼|XOM183.42+3.51 (+1.95%) ▲|
13.7 C
New York
Wednesday, October 28, 2026

Tag: TRI SVY

newsFORsourcecompanycontentinformation1releasesmarket

Opella: New study demonstrates successful cough treatment extends beyond symptom relief

PARIS, Oct. 15, 2026 /PRNewswire/ -- A new real-world study from Opella, the maker of Mucosolvan and Bisolvon, provides pharmacists with compelling evidence that...

Continuous Glucose Monitors Help Type 2 Diabetes Patients Spend Five More Hours a Day in Healthy Blood Sugar Range

A new large scale clinical trial provides the strongest evidence yet that CGMs can significantly improve blood sugar in people with type 2 diabetes...

New Study Links ADHD to More Than Fourfold Higher Hazard of Cognitive Impairment

Dr. Daniel Amen calls for greater attention to lifelong brain health following research involving more than 187,000 adults.NEWPORT BEACH, Calif., Oct. 14, 2026 /PRNewswire/...

Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting

Key Highlights:Tegoprazan is the first and only P-CAB reported to demonstrate clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a...

Human Milk Offers a Window Into Mammary Gland Function–and Its Links to Infant Growth

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- A study led by researchers at NYU Grossman School of Medicine identified shared molecular patterns in human milk...

AI May Help Catch Heart Transplant Rejection Without Biopsies

NEW YORK, Oct. 6, 2026 /PRNewswire/ -- By analyzing heart rhythm recordings and blood tests, artificial intelligence may accurately flag when a transplant patient's...

Cognision Publishes Landmark Study Showing Ketamine Produces Opposite Brain Effects in Different Patients — and That Outcome Can Be Predicted Using EEG

LOUISVILLE, Ky., June 11, 2026 /PRNewswire/ -- Cognision, a leader in neurophysiological biomarker research, today announced the publication of a landmark study in Biological...

New Case Series on Umbilical Tissue in Plantar Fascia Applications Demonstrates Clinical Reproducibility

Case Series by Dr. Robert Parker, DPM, Published in Archives of Clinical...

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren’s Disease at EULAR 2026

- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic...

Breakthrough T1D-Authored Paper Paves the Way for Beta Cell Replacement Therapies on the Path to Cures for Type 1 Diabetes

Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits NEW YORK, Aug....

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...

Interventional Robot’s RCT Research Published in JNIS, a Leading Journal in Neurointervention!

SHANGHAI, July 28, 2025 /PRNewswire/ -- The multicenter, randomized controlled trial (RCT) results of the PANVIS-A® NeuroInterventional Robotic System—led by Professor Liu Jianmin (Changhai Hospital)...

Analysis Group Co-Authors Examine the Advancements in and Application of Health Economics and Outcomes Research to the Evaluation of Cell and Gene Therapies for...

BOSTON, July 22, 2025 /PRNewswire/ -- In a new article published in Value in Health, researchers from Analysis Group, a global leader in health economics...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTRI SVY

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers